Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Purchased by IFM Investors Pty Ltd

IFM Investors Pty Ltd increased its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 55.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,921 shares of the biopharmaceutical company’s stock after purchasing an additional 8,927 shares during the period. IFM Investors Pty Ltd’s holdings in Alexion Pharmaceuticals were worth $2,441,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Nuveen Asset Management LLC grew its stake in shares of Alexion Pharmaceuticals by 57,650.8% in the 2nd quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock valued at $476,393,000 after buying an additional 3,630,846 shares during the period. Renaissance Technologies LLC grew its stake in shares of Alexion Pharmaceuticals by 104.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,642,542 shares of the biopharmaceutical company’s stock valued at $215,140,000 after buying an additional 840,742 shares during the period. Swedbank grew its stake in shares of Alexion Pharmaceuticals by 95.5% in the 2nd quarter. Swedbank now owns 1,429,397 shares of the biopharmaceutical company’s stock valued at $187,222,000 after buying an additional 698,096 shares during the period. Prudential Financial Inc. grew its stake in shares of Alexion Pharmaceuticals by 87.0% in the 2nd quarter. Prudential Financial Inc. now owns 1,180,067 shares of the biopharmaceutical company’s stock valued at $154,565,000 after buying an additional 549,063 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Alexion Pharmaceuticals by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 16,649,126 shares of the biopharmaceutical company’s stock valued at $2,180,703,000 after buying an additional 211,960 shares during the period. Institutional investors own 94.68% of the company’s stock.

A number of equities analysts recently weighed in on the stock. TheStreet cut shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Thursday, August 15th. Piper Jaffray Companies set a $180.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, September 6th. BidaskClub raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 11th. Citigroup set a $150.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 30th. Finally, Credit Suisse Group lowered their price objective on shares of Alexion Pharmaceuticals from $154.00 to $146.00 and set an “outperform” rating for the company in a research report on Friday, September 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $159.00.

Alexion Pharmaceuticals stock traded down $0.02 during mid-day trading on Friday, reaching $108.03. 5,969 shares of the company’s stock were exchanged, compared to its average volume of 1,805,602. The company has a market cap of $23.73 billion, a P/E ratio of 15.25, a P/E/G ratio of 1.02 and a beta of 1.65. Alexion Pharmaceuticals, Inc. has a twelve month low of $92.56 and a twelve month high of $141.86. The company has a quick ratio of 3.45, a current ratio of 3.98 and a debt-to-equity ratio of 0.25. The company has a fifty day moving average of $102.36 and a 200-day moving average of $115.77.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period in the prior year, the business earned $2.02 EPS. The firm’s quarterly revenue was up 23.0% on a year-over-year basis. Equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 9.41 earnings per share for the current fiscal year.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: Stop Order Uses For Individual Investors

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply